Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Longleaf Partners Global Fund Ross Glotzbach | “Abbott Laboratories ($ABT) is a globally diversified healthcare company operating across medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. The manager established a new long position during the second quarter following a steep 40% share price decline, viewing the selloff as an extreme market overreaction to transitory integration costs and industry-wide headwinds. Abbott possesses an exceptionally wide economic moat characterized by high switching costs in medical technologies, entrenched hospital relationships, and mission-critical consumer healthcare brands. These attributes produce consistent pricing power, predictable recurring cash flows, and high returns on invested capital. Historically, Abbott has demonstrated strong operating leverage, compounding earnings per share at high-single to low-double-digit rates across multi-decade periods, supported by a resilient balance sheet and secure dividend growth. Key catalysts include a return to baseline double-digit EPS growth as Exact Sciences synergies materialize, resolution of lingering infant nutrition litigation liabilities, and potential portfolio optimization via corporate spin-offs or asset sales. Risks include regulatory reimbursement cuts, medtech supply disruption, and execution snags in M&A integration.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Alpha Wealth Funds - The Insiders Fund Harvey Sax | “Abbott Laboratories ($ABT) makes up 3.4% of the fund's capital. As a diversified global healthcare company established in 1888, Abbott maintains leadership positions across medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. The manager maintains a constructive, bullish posture toward this Dividend King, viewing it as a top-tier defensive compounder whose long-term growth profile has been invigorated by strategic acquisitions. Abbott's competitive advantage lies in its extensive portfolio diversification, global distribution reach, and massive scale in continuous glucose monitoring (FreeStyle Libre). These business units provide steady, recurring cash flows, predictable returns on capital, and pricing power that have funded more than 50 consecutive years of dividend increases. Operating leverage is set to expand as multi-cancer early detection diagnostics are integrated into its sales channels. Upcoming catalysts include commercializing new FDA-approved electrophysiology catheters (TactiFlex Duo) and closing the $21 billion acquisition of Exact Sciences to capture next-generation oncology screening markets. Principal risks involve regulatory integration challenges from large-scale M&A, post-settlement scrutiny of nutrition lines, and periodic insider profit-taking.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Longleaf Partners Fund Southeastern Asset Management, Inc. | “Abbott Laboratories is a diversified global healthcare company operating across medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. Abbott represents 5.0% of the fund's portfolio. The manager initiated this holding following an excessive ~40% share price drawdown caused by transitory headwinds, seeing an attractive entry point into an elite compounder with a durable long-term track record. The investment rationale rests on Abbott's wide economic moat, supported by diversified cash-generative business units with significant pricing power and market share dominance. Digestion of major acquisitions and transient litigation noise in infant nutrition previously suppressed valuation multiples, providing an opportunity to acquire high-single to low-double-digit long-term earnings growth and consistent free cash flow conversion at a substantial discount. Near-term catalysts include resolving infant nutrition liabilities, realizing post-merger integration efficiencies, and exploring potential strategic corporate spin-offs or divestitures. Core downside risks consist of broader medtech procedural disruptions, supply chain inflation, and unexpected legal or regulatory findings in consumer health.” | BULL | Q3 2026 Oct 13, 2026 | View Pitch |
Matrix Large Cap Value Strategy Matrix Asset Advisors, Inc. | “ABT is a diversified global healthcare company that operates across four primary business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. We believe” | NEUTRAL | Q2 2026 Jul 30, 2026 | View Pitch |
Matrix Large Cap Value Strategy Matrix Asset Advisors, Inc. | “ABT is a diversified global healthcare company that operates across four primary business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmace...” | BULL | Q2 2026 Jul 30, 2026 | View Pitch |
Alpha Wealth Funds - The Insiders Fund Harvey Sax | “Abbott Laboratories is a global healthcare leader focused on life-changing technologies. Founded in 1888, the company operates across four primary segments: Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutrition. Abbott is widely recognized for its Dividend King status, having increased its dividend for over 50 consecutive years. In late June 2026, the U.S. Department of Justice officially closed its criminal probe into Abbott's Sturgis, Michigan infant formula plant (tied to the 2022 bacterial contamination and nationwide shortages). The DOJ opted to pursue civil penalties under the False Claims Act instead. This removes a massive legal and criminal overhang that has suppressed the stock for years, offering investors much clearer visibility on Abbott's remaining legal liabilities. The purchase of Exact Sciences provides them a Grail-like MCED cancer diagnostic to test their already robust product line. Abbott Laboratories is a dividend king so whenever we have an opportunity to buy a blue chip confirmed by insider buying, it's almost an automatic buy. We are underwater by about 7% and have been adding to this position.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
“At the end of the day, it was always something with Abbott. Whether it was an inventory adjustment in China, a division every now and again that fell short of plan and required a leadership change or” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.